• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    New insider Jye Chay Weei claimed no ownership of stock in the company (SEC Form 3)

    4/16/25 3:49:51 PM ET
    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TTNP alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Jye Chay Weei

    (Last) (First) (Middle)
    C/O TITAN PHARMACEUTICALS, INC.
    10 EAST 53RD STREET, SUITE 3001

    (Street)
    NEW YORK NY 10022

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    03/20/2025
    3. Issuer Name and Ticker or Trading Symbol
    TITAN PHARMACEUTICALS INC [ TTNP ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    CHIEF EXECUTIVE OFFICER
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock 0(1) D
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. No securities are beneficially owned.
    /s/ Chay Weei Jye 04/16/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $TTNP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TTNP

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TTNP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Titan Pharmaceuticals upgraded by Maxim Group with a new price target

      Maxim Group upgraded Titan Pharmaceuticals from Hold to Buy and set a new price target of $11.00

      2/25/21 10:45:32 AM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Titan Pharmaceuticals upgraded by Maxim Group

      Maxim Group upgraded Titan Pharmaceuticals from Hold to Buy

      2/18/21 8:31:20 AM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Titan Pharmaceuticals upgraded by Maxim Group with a new price target

      Maxim Group upgraded Titan Pharmaceuticals from Hold to Buy and set a new price target of $11.00

      2/18/21 7:31:23 AM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TTNP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Loh Gabriel claimed no ownership of stock in the company (SEC Form 3)

      3 - TITAN PHARMACEUTICALS INC (0000910267) (Issuer)

      5/5/25 1:50:21 PM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • New insider Jye Chay Weei claimed no ownership of stock in the company (SEC Form 3)

      3 - TITAN PHARMACEUTICALS INC (0000910267) (Issuer)

      4/16/25 3:49:51 PM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • New insider Mokhtar Firdauz claimed no ownership of stock in the company (SEC Form 3)

      3 - TITAN PHARMACEUTICALS INC (0000910267) (Issuer)

      4/5/24 10:14:05 AM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TTNP
    Leadership Updates

    Live Leadership Updates

    See more

    $TTNP
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $TTNP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $TTNP
    SEC Filings

    See more
    • Titan Pharmaceuticals, Inc. Announces Receipt of Notice from Nasdaq

      NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan") today reported that it received a notice (the "5250 Notice") on November 22, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") advising the Company that it was not in compliance with Nasdaq's continued listing requirements under the Nasdaq Listing Rule 5250(c)(1) ("Rule 5250") as a result of its failure to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (the "Q3 Form 10-Q") in a timely manner. Under Nasdaq rules, the Company has 60 calendar days from receipt of the 5250 Notice or until January 21, 2025, to submit a plan to

      11/27/24 4:05:55 PM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Titan Pharmaceuticals Announces Appointment of Dato' Seow Gim Shen and Brynner Chaim to the Company's Board of Directors

      SAN FRANCISCO, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") is pleased to announce the appointments of Dato' Seow Gim Shen and Brynner Chiam to the Company's Board of Directors, effective October 12, 2023. Mr. Shen has also been appointed Chairman of the Board. Simultaneous with the election of Mr. Shen and Mr. Chiam to the Board, David E. Lazar and Peter L. Chasey each submitted their resignations from the Board, effective immediately. These resignations were not the result of any disagreements with the Company relating to the Company's operations, policies or practices. Mr. Lazar will remain with the Company as Chief Execut

      10/16/23 4:37:23 PM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Titan Pharmaceuticals Announces $1 Million Private Placement of Convertible Preferred Stock

      NEW YORK, April 11, 2025 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") announced today that, pursuant to a securities purchase agreement (the "Purchase Agreement") with Blue Harbour Asset Management L.L.C-FZ ("Blue Harbour"), it has completed a private placement of the Company's newly designated Series B Convertible Preferred Stock (the "Preferred Stock"). Pursuant to the Purchase Agreement, Blue Harbour purchased 100,000 shares of Preferred Stock for an aggregate purchase price of $1,000,000. The shares have a conversion price of $3.00. The Certificate of Designations authorizing the Preferred Stock contains a beneficial ownership conversion "bl

      4/11/25 4:15:09 PM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Titan Pharmaceuticals, Inc. Announces Receipt of Notice from Nasdaq

      NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan") today reported that it received a notice (the "5250 Notice") on November 22, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") advising the Company that it was not in compliance with Nasdaq's continued listing requirements under the Nasdaq Listing Rule 5250(c)(1) ("Rule 5250") as a result of its failure to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (the "Q3 Form 10-Q") in a timely manner. Under Nasdaq rules, the Company has 60 calendar days from receipt of the 5250 Notice or until January 21, 2025, to submit a plan to

      11/27/24 4:05:55 PM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Titan Pharmaceuticals Enters Into Merger Agreement With KE Sdn. Bhd.

      NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan") today announced that it has entered into a Merger and Contribution and Share Exchange Agreement (the "Merger Agreement") regarding a business combination with KE Sdn. Bhd. ("KE"). The Merger Agreement was approved by Titan's board of directors (the "Board"). If the Merger Agreement is approved by the stockholders of Titan and KE (and the other closing conditions are satisfied or waived in accordance with the Merger Agreement), and upon consummation of the transactions contemplated by the Merger Agreement (the "Closing"), Titan will be combined with KE in a "reverse merger" transaction consisting

      8/19/24 4:11:12 PM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Titan Pharmaceuticals Inc.

      SC 13D/A - TITAN PHARMACEUTICALS INC (0000910267) (Subject)

      8/21/24 8:32:38 AM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Titan Pharmaceuticals Inc. (Amendment)

      SC 13D/A - TITAN PHARMACEUTICALS INC (0000910267) (Subject)

      4/5/24 4:34:04 PM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D filed by Titan Pharmaceuticals Inc.

      SC 13D - TITAN PHARMACEUTICALS INC (0000910267) (Subject)

      10/4/23 5:30:18 PM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Titan Pharmaceuticals Inc.

      10-Q - TITAN PHARMACEUTICALS INC (0000910267) (Filer)

      5/14/25 4:05:26 PM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Titan Pharmaceuticals Inc.

      DEFA14A - TITAN PHARMACEUTICALS INC (0000910267) (Filer)

      5/2/25 4:11:23 PM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Titan Pharmaceuticals Inc.

      DEF 14A - TITAN PHARMACEUTICALS INC (0000910267) (Filer)

      5/2/25 4:05:25 PM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care